目录号 | 产品详情 | 靶点 | |
---|---|---|---|
T62444 | |||
NBI-27914 是一种有效的、选择性的 CRFR1 拮抗剂。其中 CRF 受体 CRFR1 和 CRFR2 是 G 蛋白偶联受体超家族的成员。 | |||
TP1020 | |||
Endogenous CRF agonist. Ki values are 13, 1.5 and 0.97 nM for hCRF1, rCRF2α and mCRF2β respectively. | |||
T75976 | |||
Urotensin I (Catostomus urotensin I) TFA 是一种类 CRF 样肽,可作为 CRF 受体激动剂,在细胞实验中,对人 CRF1,CRF2和大鼠 CRF2α受体的 pEC50值分别为 11.46,9.36 和 9.85,对 hCRF1,rCRF2α和 mCRF2β受体的 Ki 值分别为 0.4,1.8 和 5.7 nM。 | |||
T76510 | |||
[Asu1,6-Arg8]Vasopressin 是一种加压素 (vasopressin) 激动剂,可增强培养的大鼠垂体前叶细胞中由促肾上腺皮质激素释放因子 (CRF) 诱导的环AMP 积累和ACTH 释放。 | |||
TP1860 | |||
Human urocortin (hUcn) II is a new member of the corticotropin-releasing-factor (CRF) family. It selectively binds to the CRF2 receptor. | |||
T75804 | |||
K41498 TFA 是一种强选择性的CRF2 receptor 拮抗剂,其对人 CRF2α、CRF2β和 CRF1受体的Ki 值分别为 0.66 nM、0.62 nM 和425 nM。K41498 TFA 是 antisauvagine-30 (aSvg-30) 的类似物,可抑制 sauvagine 刺激的 cAMP 在 hCRF2α/hCRF2β表达细胞中的积累。K41498 可用于低血压研究。 | |||
T35814 | |||
Urocortin III is a neuropeptide hormone and member of the corticotropin-releasing factor (CRF) family which includes mammalian CRF , urocortin , urocortin II , frog sauvagine, and piscine urotensin I.1 Human urocortin III shares 90, 40, 37, and 21% identity to mouse urocortin III , mouse urocortin II , human urocortin , and mouse urocortin, respectively. Urocortin III selectively binds to type 2 CRF receptors (Kis = 21.7, 13.5, and >100 nM for rat CRF2α, rat CRF2β, and human CRF1, respectively). It stimulates cAMP production in CHO cells expressing rat CRF2α and mouse CRF2β (EC50s = 0.16 and 0.12 nM, respectively) as well as cultured anterior pituitary cells expressing endogenous CRF2β. Urocortin III is co-released with insulin to potentiate glucose-stimulated somatostatin release in vitro in human pancreatic β-cells.2 In vivo, urocortin III reduces food intake in a dose- and time-dependent manner in mice with a minimum effective dose (MED) of 0.3 nmol/animal.3 It increases swimming time in a forced swim test in mice, indicating antidepressant-like activity.4References1. Lewis, K., Li, C., Perrin, M.H., et al. Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc. Natl. Acad. Sci. U.S.A. 98(13), 7570-7575 (2001).2. van der Meulen, T., Donaldson, C.J., Cáceres, E., et al. Urocortin3 mediates somatostatin-dependent negative feedback control of insulin secretion. Nat. Med. 21(7), 769-776 (2015).3. Pelleymounter, M.A., Joppa, M., Ling, N., et al. Behavioral and neuroendocrine effects of the selective CRF2 receptor agonists urocortin II and urocortin III. Peptides 25(4), 659-666 (2004).4. Tanaka, M., Kádár, K., Tóth, G., et al. Antidepressant-like effects of urocortin 3 fragments. Brain Res. Bull. 84(6), 414-418 (2011). Urocortin III is a neuropeptide hormone and member of the corticotropin-releasing factor (CRF) family which includes mammalian CRF , urocortin , urocortin II , frog sauvagine, and piscine urotensin I.1 Human urocortin III shares 90, 40, 37, and 21% identity to mouse urocortin III , mouse urocortin II , human urocortin , and mouse urocortin, respectively. Urocortin III selectively binds to type 2 CRF receptors (Kis = 21.7, 13.5, and >100 nM for rat CRF2α, rat CRF2β, and human CRF1, respectively). It stimulates cAMP production in CHO cells expressing rat CRF2α and mouse CRF2β (EC50s = 0.16 and 0.12 nM, respectively) as well as cultured anterior pituitary cells expressing endogenous CRF2β. Urocortin III is co-released with insulin to potentiate glucose-stimulated somatostatin release in vitro in human pancreatic β-cells.2 In vivo, urocortin III reduces food intake in a dose- and time-dependent manner in mice with a minimum effective dose (MED) of 0.3 nmol/animal.3 It increases swimming time in a forced swim test in mice, indicating antidepressant-like activity.4 References1. Lewis, K., Li, C., Perrin, M.H., et al. Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc. Natl. Acad. Sci. U.S.A. 98(13), 7570-7575 (2001).2. van der Meulen, T., Donaldson, C.J., Cáceres, E., et al. Urocortin3 mediates somatostatin-dependent negative feedback control of insulin secretion. Nat. Med. 21(7), 769-776 (2015).3. Pelleymounter, M.A., Joppa, M., Ling, N., et al. Behavioral and neuroendocrine effects of the selective CRF2 receptor agonists urocortin II and urocortin III. Peptides 25(4), 659-666 (2004).4. Tanaka, M., Kádár, K., Tóth, G., et al. Antidepressant-like effects of urocortin 3 fragments. Brain Res. Bull. 84(6), 414-418 (2011). | |||
TP2121 | |||
Corticotropin-releasing factor (CRF) receptor agonist. Ki values are 9.4, 9.9, and 3.8 nM for inhibition of 125I-[D-Tyr1]astressin binding to hCRF-R1, rCRF-R2a and mCRF-R2b respectively. | |||
T75894 | |||
Sauvagine TFA,是一种来自青蛙皮肤的 40 个氨基酸的神经肽,是哺乳动物 CRF 激动剂。Sauvagine TFA 可有效从大鼠垂体细胞释放 ACTH。Sauvagine TFA 在利尿,心血管系统和内分泌腺体方面具有许多药理作用。 | |||
T76360 | |||
a-Helical Corticotropin Releasing Factor (12-41),一种含有30个氨基酸的α螺旋促肾上腺皮质激素释放因子/激素类似物。作为下丘脑激素的促肾上腺皮质激素释放因子 (CRF) 能促进肾上腺皮质激素 (ACTH) 分泌,而a-Helical Corticotropin Releasing Factor (12-41) 则抑制该刺激效应。 |
目录号 | 产品名/同用名 | 种属 | 表达系统 | ||
---|---|---|---|---|---|
TMPJ-00906 | CRHBP Protein, Human, Recombinant (His) | Human | Human Cells | ||
Corticotropin-Releasing Factor-Binding Protein (CRHBP) is a 37 kDa secreted glycoprotein that binds both CRH and urocortin in a 42 kDa extracellular complex. The molecule is approximately 300 amino acids in length and demonstrates five intrachain disulfide bonds. Difference between CRHBP from different species exist, human CRHBP is found in plasma while rodent and sheep CRHBP is limited to neuroendocrine tissues. CRHBP may inactivate CRH and may prevent inappropriate pituitary-adrenal stimulation in pregnancy. CRHBP is presumed to either sequester CRH, rendering it unavailable to cells or transport it to target tissues. Although CRF-BP concentration in the human peripheral circulation is normally low, it increases throughout pregnancy and fall back rapidly after parturition.
|
|||||
TMPY-03412 | GGCT Protein, Human, Recombinant (His) | Human | E. coli | ||
GGCT belongs to the gamma-glutamylcyclotransferase family. It catalyzes the formation of 5-oxoproline from gamma-glutamyl dipeptides, the penultimate step in glutathione catabolism. GGCT may play a significant role in glutathione homeostasis. GGCT also induces release of cytochrome c from mitochondria with resultant induction of apoptosis. Pseudogenes of GGCT gene are located on the long arm of chromosome 5 and the short arm of chromosomes 2 and 2. Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene.
|
|||||
TMPY-01373 | HIV-1 (group M, subtype CRF07_BC) gp120 Protein (His) | HIV | HEK293 | ||
The HIV-1 gp120 envelope protein, a glycoprotein that is part of the outer layer of the virus, is an essential component in the multi-tiered viral entry process. It presents itself as viral membrane spikes consisting of 3 molecules of gp120 linked together and anchored to the membrane by gp41 protein. Gp120 is essential for viral infection as it facilitates HIV entry into the host cell and this is its best-known and most researched role in HIV infection. However, it is becoming increasingly evident that gp120 might also be facilitating viral persistence and continuing HIV infection by influencing the T cell immune response to the virus. The surface protein gp120 attaches the virus to the host lymphoid cell by binding to the primary receptor CD4. Gp120 binding to its receptor CD4 and co-receptor, CXCR4 or CCR5 is required for fusion of viral and cellular membranes. Several mechanisms might be involved in this process of which gp120 binding to the CD4 receptor of T cells is the best known and most important interaction as it facilitates viral entry into the CD4+ cells and their depletion, a hallmark of the HIV infection. Gp120 is shed from the viral membrane and accumulates in lymphoid tissues in significant amounts. Despite the overall genetic heterogeneity of the gp120 glycoprotein, the conserved CD4 binding site provides an attractive antiviral target. Interaction between gp120 and ITGA4/ITGB7 would allow the virus to enter GALT early in the infection, infecting and killing most of GALT's resting CD4+ T-cells. This T-cell depletion is believed to be the major insult to the host immune system leading to AIDS.
|
|||||
TMPH-02608 | Corticoliberin Protein, Mouse, Recombinant (His & KSI) | Mouse | E. coli | ||
Hormone regulating the release of corticotropin from pituitary gland. Induces NLRP6 in intestinal epithelial cells, hence may influence gut microbiota profile.
|
|||||
TMPY-02882 | HIV-1 (group M, subtype CRF07_BC) gp140 Protein (His) | HIV | HEK293 | ||
HIV-1 (group M, subtype CRF07_BC) gp140 Protein (His) is expressed in HEK293 with His tag. The predicted molecular weight is 78.2 kDa.
|
|||||
TMPH-02555 | C1QL1 Protein, Mouse, Recombinant (His) | Mouse | Yeast | ||
May regulate the number of excitatory synapses that are formed on hippocampus neurons. Has no effect on inhibitory synapses.
|
|||||
TMPY-01408 | HIV-1 (group M, subtype CRF07_BC) gp140 Protein (hFc) | HIV | HEK293 | ||
HIV-1 (group M, subtype CRF07_BC) gp140 Protein (hFc) is expressed in HEK293 with Fc tag. The predicted molecular weight is 98 kDa.
|
|||||
TMPY-06486 | HIV-1 (group M, subtype CRF07_BC) gp120 Protein (His), Biotinylated | HIV | HEK293 | ||
The HIV-1 gp120 envelope protein, a glycoprotein that is part of the outer layer of the virus, is an essential component in the multi-tiered viral entry process. It presents itself as viral membrane spikes consisting of 3 molecules of gp120 linked together and anchored to the membrane by gp41 protein. Gp120 is essential for viral infection as it facilitates HIV entry into the host cell and this is its best-known and most researched role in HIV infection. However, it is becoming increasingly evident that gp120 might also be facilitating viral persistence and continuing HIV infection by influencing the T cell immune response to the virus. The surface protein gp120 attaches the virus to the host lymphoid cell by binding to the primary receptor CD4. Gp120 binding to its receptor CD4 and co-receptor, CXCR4 or CCR5 is required for fusion of viral and cellular membranes. Several mechanisms might be involved in this process of which gp120 binding to the CD4 receptor of T cells is the best known and most important interaction as it facilitates viral entry into the CD4+ cells and their depletion, a hallmark of the HIV infection. Gp120 is shed from the viral membrane and accumulates in lymphoid tissues in significant amounts. Despite the overall genetic heterogeneity of the gp120 glycoprotein, the conserved CD4 binding site provides an attractive antiviral target. Interaction between gp120 and ITGA4/ITGB7 would allow the virus to enter GALT early in the infection, infecting and killing most of GALT's resting CD4+ T-cells. This T-cell depletion is believed to be the major insult to the host immune system leading to AIDS.
|
|||||
TMPY-04061 | HIV-2 (subtype CRF01_AB, strain 07JP_NMC716_clone_01) gp36 Protein (His & MBP) | HIV | E. coli | ||
HIV-2 (subtype CRF01_AB, strain 07JP_NMC716_clone_01) gp36 Protein (His & MBP) is expressed in E. coli with His and MBP tag. The predicted molecular weight is 58.8 kDa. Accession number: L8B302
|
|||||
TMPK-00474 | IL-22RA1 Protein, Cynomolgus, Recombinant (His) | Cynomolgus | HEK293 | ||
IL-22 receptor, also known as IL-22 R alpha 1 and CRF2-9, is an approximately 65 kDa transmembrane glycoprotein in the type II cytokine receptor family (CRF).Component of the receptor for IL20, IL22 and IL24. Component of IL22 receptor formed by IL22RA1 and IL10RB enabling IL22 signaling via JAK/STAT pathways. IL22 also induces activation of MAPK1/MAPK3 and Akt kinases pathways. Component of one of the receptor for IL20 and IL24 formed by IL22RA1 and IL20RB also signaling through STATs activation. Mediates IL24 antiangiogenic activity as well as IL24 inhibitory effect on endothelial cell tube formation and differentiation.
|